-
公开(公告)号：US20250059499A1
公开(公告)日：2025-02-20
申请号：US18573200
申请日：2022-06-22
Inventor： Jayachandran N. KIZHAKKEDATHU , Erika M.J. SIREN , Jonathan C. CHOY , Haiming D. LUO , Stephen G. WITHERS , Caigan DU , Winnie ENNS
Abstract: Provided herein are compounds including a linear polyglycerol, a peptide tag, with either a linker-sugar-sialic acid moiety or a sulfate group, a preservation solutions including the compounds, methods for using the compounds or the preservation solutions to cell surface engineering (CSE) of a cell, a tissue, an organ for transplant, and methods for making the compounds. In particular, the CSE may recapitulate or rebuild glycocalyx on the luminal endothelial surface of an organ to limit immune rejection of the organ after transplant.
-
2.发明申请公开(公告)号：US20220380785A1
公开(公告)日：2022-12-01
申请号：US17773543
申请日：2020-11-01
Applicant: THE UNIVERSITY OF BRITISH COLUMBIA
Inventor： Stephen G. WITHERS , Lyann SIM , Warren William WAKARCHUK
Abstract: Provided herein are enzymatic compositions for protein O-glycosylation and sialylation, methods and systems associated therewith. In particular, the composition for in vivo sialylation of therapeutic proteins. The composition comprises a polypeptide N-acetylgalactosaminyltransferase; a β-1,3-galactosyltransferase; an UDP-Glc/GlcNAc 4-epimerase; a disulfide bond isomerase; and an α-2,3-sialyltransferase or an α-2,6-sialyltransferase. Furthermore, provided herein are compositions for efficient and complete O-glycosylation and di-sialylation of therapeutic proteins.
-
公开(公告)号：US20210345601A1
公开(公告)日：2021-11-11
申请号：US17269238
申请日：2019-08-16
Inventor： Marcelo CYPEL , Aizhou WANG , Shafique KESHAVJEE , Stephen G. WITHERS , Peter RAHFELD , Jayachandran KIZHAKKEDATHU
Abstract: Provided herein are perfusion fluids for enzymatically cleaving A-antigens from a donor organ, and methods, uses, associated therewith. In particular, the perfusion fluids comprise two enzymes, GalNAcDeacetylase and Galactosaminidase and the fluids may further comprise a buffered extracellular solution and/or a crowing agent. Furthermore, the compositions described herein were found to have activity at temperatures and pH levels suitable for cell viability.
-
Patent Agency Ranking
公开(公告)号：US20170121361A1
公开(公告)日：2017-05-04
申请号：US15119622
申请日：2015-02-18
Applicant: The University of British Columbia
Inventor： Stephen G. WITHERS , Thomas J. MORLEY , Lars BAUMANN
CPC classification number: C07H13/02 , A61K47/549 , C07H5/02 , C07H15/203 , C07H17/075 , C07H19/10 , C07K1/1077 , C08H1/00 , C12P19/18 , C12P19/26 , C12P21/005
Abstract: This invention provides compound having a structure of Formulas: Furthermore, methods and uses of such compounds for covalently bonding to a sugar acceptor, to form modified protein therapeutics having reduced enzymatic hydrolysis, improved biological stability or an improved pharmacokinetic property.
-
公开(公告)号：US20250011749A1
公开(公告)日：2025-01-09
申请号：US18628538
申请日：2024-04-05
Applicant: The University of British Columbia
Inventor： Stephen G. WITHERS , Peter RAHFELD , Jayachandran KIZHAKKEDATHU
Abstract: Provided herein are enzymatic compositions for carbohydrate antigen cleavage, methods, uses, apparatuses and sys-O tems associated therewith. In particular, the composition comprises two enzymes, GalNAcDeacetylase and Galactosaminidase and the el composition may further comprise a crowding agent. Furthermore, the compositions described herein were found to have activity a C) temperatures and pH levels suitable for cell viability.
-
公开(公告)号：US20210324361A1
公开(公告)日：2021-10-21
申请号：US17269235
申请日：2019-08-16
Applicant: THE UNIVERSITY OF BRITISH COLUMBIA
Inventor： Stephen G. WITHERS , Peter RAHFELD , Jayachandran KIZHAKKEDATHU
Abstract: Provided herein are enzymatic compositions for carbohydrate antigen cleavage, methods, uses, apparatuses and systems associated therewith. In particular, the composition comprises two enzymes, GalNAcDeacetylase and Galactosaminidase and the composition may further comprise a crowding agent. Furthermore, the compositions described herein were found to have activity a temperatures and pH levels suitable for cell viability.
-
7.发明公开公开(公告)号：US20240294895A1
公开(公告)日：2024-09-05
申请号：US18441770
申请日：2024-02-14
Inventor： Marcelo CYPEL , Aizhou WANG , Shafique KESHAVJEE , Stephen G. WITHERS , Peter RAHFELD , Jayachandran KIZHAKKEDATHU
CPC classification number: C12N9/80 , A01N1/0226 , C12N9/2402 , C12N11/00 , C12Y302/01049 , C12Y305/01025 , C07K2319/00
Abstract: Provided herein are perfusion fluids for enzymatically cleaving A-antigens from a donor organ, and methods. uses. associated therewith. In particular, the perfusion fluids comprise two enzymes. GalNAcDeacetylase and Galactosaminidase and the fluids may further comprise a buffered extracellular solution and/or a crowing agent. Furthermore. the compositions described herein were found to have activity at temperatures and ph levels suitable for cell viability.
-
8.发明申请公开(公告)号：US20180193413A1
公开(公告)日：2018-07-12
申请号：US15740494
申请日：2016-06-29
Applicant: THE UNIVERSITY OF BRITISH COLUMBIA
Inventor： Stephen G. WITHERS , Andrew TARLING , Raymond J. ANDERSEN , Gary D. BRAYER , Robert KEYZERS , Christina Rose TYSOE , Leslie Karen WILLIAMS
CPC classification number: A61K38/17 , A61K9/0053 , A61K38/00 , A61P1/16 , A61P3/00 , A61P31/12 , C12N9/24
Abstract: Provided are methods, uses and pharmaceutical compositions for inhibition of mammalian alpha-amylase in a subject, with a Helianthamide peptide or a derivative thereof in a biologically effective amount. The subject in need of alpha-amylase inhibition, may have or be at risk of developing one or more of the following: Middleton syndrome; a motility disorder of the gastrointestinal tract; postprandial reactive hypoglycemia; postprandial syndrome; irritable bowel syndrome; diabetes mellitus type 1; diabetes mellitus type 2; pre-diabetes; obesity, dumping syndrome; infant dumping syndrome; polycystic ovary syndrome; steatohepatitis; and viral infection.
-
-
-
-
-
-
-
Search Results
8
records
(took 0.027 seconds)
